Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Lexaria Bioscience (LEXX) over the last 14 years, with Q4 2025 value amounting to $74895.0.

  • Lexaria Bioscience's Share-based Compensation fell 2466.43% to $74895.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $834974.0, marking a year-over-year increase of 5528.68%. This contributed to the annual value of $859494.0 for FY2025, which is 7461.01% up from last year.
  • As of Q4 2025, Lexaria Bioscience's Share-based Compensation stood at $74895.0, which was down 2466.43% from $122724.0 recorded in Q3 2025.
  • In the past 5 years, Lexaria Bioscience's Share-based Compensation registered a high of $470136.0 during Q2 2025, and its lowest value of $9634.0 during Q3 2023.
  • In the last 5 years, Lexaria Bioscience's Share-based Compensation had a median value of $99415.0 in 2024 and averaged $159454.0.
  • In the last 5 years, Lexaria Bioscience's Share-based Compensation tumbled by 9586.3% in 2023 and then skyrocketed by 90176.46% in 2024.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Share-based Compensation stood at $408544.0 in 2021, then crashed by 83.17% to $68776.0 in 2022, then decreased by 21.55% to $53953.0 in 2023, then skyrocketed by 84.26% to $99415.0 in 2024, then decreased by 24.66% to $74895.0 in 2025.
  • Its Share-based Compensation was $74895.0 in Q4 2025, compared to $122724.0 in Q3 2025 and $470136.0 in Q2 2025.